Thomas Crowley Miglietta, PA | |
100 Kenyon Ave, Wakefield, RI 02879-4216 | |
(401) 782-8000 | |
Not Available |
Full Name | Thomas Crowley Miglietta |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 100 Kenyon Ave, Wakefield, Rhode Island |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1457847790 | NPI | - | NPPES |
1457847790 | Medicaid | RI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | (* (Not Available)) | Secondary |
363A00000X | Physician Assistant | PA01444 (Rhode Island) | Primary |
Mailing Address | Practice Location Address |
---|---|
Thomas Crowley Miglietta, PA 2 Maynard St, Potsdam, NY 13676-1129 Ph: (203) 470-6446 | Thomas Crowley Miglietta, PA 100 Kenyon Ave, Wakefield, RI 02879-4216 Ph: (401) 782-8000 |
News Archive
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
Combined treatment with a drug that mimics the action of a gut hormone and basal insulin is more effective at improving blood sugar control than other anti-diabetic treatments, with similar rates of hypoglycaemia (dangerously low blood sugar levels) and greater weight loss, a systematic review and meta-analysis published in The Lancet shows.
Enzyme inhibitors play a pivotal role in pharmaceutical and nutraceutical industries. The primary understanding of the action of inhibitors helps pharmacologists during the design process for developing new therapeutic drugs.
The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.
› Verified 7 days ago
Michaella Elizabeth Marzullo, Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 100 Kenyon Ave, Wakefield, RI 02879 Phone: 401-782-8000 | |
Cheryl A Trager, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 46 Holley St, Suite 2, Wakefield, RI 02879 Phone: 401-783-8008 Fax: 401-783-8156 | |
Zachary Mitchell Hudson, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 High St, Wakefield, RI 02879 Phone: 401-789-1422 Fax: 401-728-6810 | |
Alyssa Millar, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 553 Kingstown Rd, Wakefield, RI 02879 Phone: 401-304-9111 | |
Lindsey Rachel Maroney, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 100 Kenyon Ave, Wakefield, RI 02879 Phone: 401-788-8000 | |
Amy Berrol, PA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 70 Kenyon Ave, Suite 215, Wakefield, RI 02879 Phone: 401-783-0084 Fax: 401-782-0005 | |
Mrs. Erin Marie Smith, PA-C Physician Assistant Medicare: May Accept Medicare Assignments Practice Location: 1 High St, Wakefield, RI 02879 Phone: 401-789-1422 Fax: 401-782-6810 |